Diabetic macular oedema: Physical, physiological and molecular factors contribute to this pathological process

Acta Ophthalmologica

Volumn 88, Issue 3, 2010, Pages 279-291

  Ehrlich, Rita ^a   Harris, Alon ^a   Ciulla, Thomas A ^b   Kheradiya, Nisha ^a   Winston, Diana M ^a   Wirostko, Barbara ^c  

^a INDIANA UNIVERSITY   (United States)

^b METHODIST HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Diabetic macular oedema; Diabetic retinopathy; Eye; Retina

Indexed keywords

ANGIOTENSIN II; CANDESARTAN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE C; SCATTER FACTOR; STEROID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

BLOOD RETINA BARRIER; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CAPILLARY FLOW; CELL JUNCTION; CHRONIC DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EYE INFLAMMATION; HUMAN; HYDROSTATIC PRESSURE; HYPERGLYCEMIA; HYPOXIA; LASER COAGULATION; MICROVASCULATURE; MOLECULAR BIOLOGY; NONHUMAN; ONCOTIC PRESSURE; OXIDATIVE STRESS; OXYGEN TENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA MACULA EDEMA; RETINOPATHY; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; TIGHT JUNCTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMANS; HYPERGLYCEMIA; MACULAR EDEMA; RETINA;

EID: 77951703383     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01501.x     Document Type: Review

References (122)

1. Aiello LP (2008 Targeting intraocular neovascularization and oedema - one drop at a time. N Engl J Med 359 : 967 969.
2. Aiello LP, Avery RL, Arrigg PG et al. (1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 : 1480 1487.
3. Angst BD, Marcozzi C Magee AI (2001 The cadherin superfamily: diversity in form and function. J Cell Sci 114 : 629 641.
4. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW (1998 Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Diabetes 47 : 1953 1959.
5. Antonetti DA, Barber AJ, Hollinger LA et al. (1999 Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumours. J Biol Chem 274 : 23463 23467.
6. Bates DO Curry FE (1997 Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol 273 : H687 H694.
7. Bazzoni G Dejana E (2004 Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84 : 869 901.
8. Behzadian MA, Wang XL, Windsor LJ et al. (2001 TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 42 : 853 859.
9. Behzadian MA, Windsor LJ, Ghaly N et al. (2003 VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 17 : 752 754.
10. Ben-Mahmud BM, Chan WH, Abdulahad RM et al. (2006 Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy. Diabetologia 49 : 2185 2191.
11. Brownlee M (2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414 : 813 820.
12. Brownlee M (2005 Banting lecture 2004: the pathobiology of diabetic complications, a unifying mechanism. Diabetes 54 : 1615 1625.
13. Bursell SE, Clermont AC, Kinsley BT et al. (1996 Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 37 : 886 897.
14. Cai W, Rook SL, Jiang ZY et al. (2000 Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol Vis Sci 41 : 1885 1893.
15. Caldwell RB, Bartoli M, Benzadian AM et al. (2005 Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Current Drug Targets 6 : 511 524.
16. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R Sjølie AK DIRECT Programme Study Group (2008 Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372 : 1394 1402.
17. Chen YH, Lin SJ, Lin FY et al. (2007 High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 56 : 1559 1568.
18. Chew E (2003 Guest editorial: a simplified diabetic retinopathy scale. Ophthalmology 110 : 1675 1676.
19. Chew EY, Klein ML, Ferris FL III. et al. (1996 Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114 : 1079 1084.
20. Ciulla TA, Harris A, Latkany P et al. (2002 Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 80 : 468 477.
21. Ciulla TA, Amador AG Zinman B (2003 Diabetic retinopathy and diabetic macular oedema: pathophysiology, screening, and novel therapies. Diabetes Care 26 : 2653 2664.
22. Clermont AC, Cahill M, Salti H et al. (2006a Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal haemodynamics. Invest Ophthalmol Vis Sci 47 : 2701 2708.
23. Clermont A, Bursell SE Feener EP (2006b Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl 24 : 73 80.
24. Cunha-Vaz JG Travassos A (1984 Breakdown of the blood-retinal barriers and cystoids macular oedema. Surv Ophthalmol 28 : 485 492.
25. Dejana E, Bazzoni G Lampugnani MG (1999 Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res 252 : 13 19.
26. Desai TR, Leeper NJ, Hynes KL et al. (2002 Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 104 : 118 123.
27. Diabetes Control and Complications Trial (DCCT) Research Group (1993 The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 : 977 986.
28. Dvorak AM Feng D (2001 The vesiculo-vacuolar organelle (VVO): a new endothelial cell permeability organelle. J Histochem Cytochem 49 : 419 432.
29. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group (1985 Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103 : 1796 1806.
30. El-Remessy AB, Abou-Mohamed G, Caldwell RW et al. (2003 High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44 : 3135 3143.
31. Erickson KK, Sundstrom JM Antonetti DA (2007 Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10 : 103 117.
32. Esser S, Lampugnani MG, Corada M et al. (1998 Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111 : 1853 1865.
33. Feke GT, Tagawa H, Yoshida A et al. (1985 Retinal circulatory changes related to retinopathy progression in insulin-dependent diabetes mellitus. Ophthalmology 92 : 1517 1522.
34. Felinski EA Antonetti DA (2005 Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 30 : 949 957.
35. Feng D, Nagy JA, Pyne K et al. (1999 Pathway of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6 : 23 44.
36. Ferrara N, Gerber HP LeCouter J (2003 The biology of VEGF and its receptors. Nat Med 9 : 669 676.
37. Ferris FL III. Patz A (1984 Macular oedema: a complication of diabetic retinopathy. Surv Ophthalmol 28 (Suppl. 452 461.
38. Funatsu H Yamashita H (2003 Pathogenesis of diabetic retinopathy and the rennin-angiotensin system. Ophthalmic Physiol Opt 23 : 495 501.
39. Funatsu H, Yamashita H, Ikeda T et al. (2002a Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular oedema and other retinal disorders. Am J Ophthalmol 133 : 537 543. (Pubitemid 34258063)
40. Funatsu H, Yamashita H, Noma H et al. (2002b Increased levels of vascular endothelial growth factor and interleukin-6 in aqueous humour of diabetics with macular oedema. Am J Ophthalmol 133 : 70 77.
41. Funatsu H, Yamashita H, Ikeda T et al. (2003 Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular oedema. Ophthalmology 110 : 1690 1696.
42. Funatsu H, Yamashita H, Sakata K et al. (2005 Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular oedema. Ophthalmology 112 : 806 816.
43. Gao BB, Clermont A, Rook S et al. (2007 Extracellular carbonic anhydrase mediates haemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13 : 181 188.
44. Giebel SJ, Menicucci G, McGuire PG et al. (2005 Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85 : 597 607.
45. Gilbert RE, Kelly DJ, Cox AJ et al. (2000 Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43 : 1360 1367.
46. Gillow JT, Gibson JM Dodson PM (1999 Hypertension and diabetic retinopathy - what's the story? Br J Ophthalmol 83 : 1083 1087.
47. Grunwald JE, Riva CE, Brucker AJ et al. (1984 Altered retinal vascular response to 100% oxygen breathing in diabetes mellitus. Ophthalmology 91 : 1447 1452.
48. Grunwald JE, DuPont J Riva CE (1996 Retinal haemodynamics in patients with early diabetes mellitus. Br J Ophthalmol 80 : 327 331.
49. Hadi HA Suwaidi JA (2007 Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3 : 853 876.
50. Harada C, Mitamura Y Harada T (2006 The role of cytokine and trophic factors in the epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res 25 : 149 164.
51. Hempel A, Maasch C, Heintze U et al. (1997 High glucose concentrations increase endothelial cell permeability via activation of protein kinase Cα. Circ Res 81 : 363 371.
52. Hirase T, Kawashima S, Wong EY et al. (2001 Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. J Biol Chem 276 : 10423 10431.
53. Hofman P, Blaauwgeers HG, Tolentino MJ et al. (2000 VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res 21 : 637 645.
54. Horton ES (1995 NIDDM - the devastating disease. Diabetes Res Clin Pract 28 (Suppl. 3 11.
55. Hudry-Clergeon H, Stengel D, Ninio E et al. (2005 Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3′-kinase. FASEB J 19 : 512 520.
56. Hughes S, Gardiner T, Hu P et al. (2006 Altered pericyte-endothelial relations in the rat retina during age: implication for vessel stability. Neurobiol Aging 27 : 1838 1847.
57. Ishii H, Koya D King GL (1998 Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76 : 21 31.
58. Kaji Y, Usui T, Ishida S et al. (2007 Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation endproducts. Invest Ophthalmol Vis Sci 48 : 858 865.
59. Kevil CG, Payne DK, Mire E et al. (1998 Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273 : 15099 15103.
60. Khaliq A, Foreman D, Ahmed A et al. (1998 Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78 : 109 116.
61. Kim I, Moon SO, Kim SH et al. (2001 Vascular endothelial growth factor expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276 : 7614 7620.
62. Klein R, Klein BE, Moss SE et al. (1995 The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The longterm incidence of macular oedema. Ophthalmology 102 : 7 16.
63. Klein R, Klein BEK, Moss SE et al. (1998 The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105 : 1801 1815.
64. Knudsen ST, Bek T, Poulsen PL et al. (2002 Macular oedema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care 25 : 2328 2334.
65. Kohner EM, Patel V Rassam SM (1995 Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 44 : 603 607.
66. Koya D, Jirousek MR, Lin YW et al. (1997 Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100 : 115 126.
67. Kristinsson JK, Gottfredsdóttir MS Stefánsson E (1997 Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 81 : 274 278.
68. Lopes de Faria JM, Jalkh AE, Trempe CL McMeel JW (1999 Diabetic macular oedema: risk factors and concomitants. Acta Ophthalmol Scand 77 : 170 175.
69. Lu M, Perez VL, Ma N et al. (1999 VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40 : 1808 1812.
70. Lynch JJ, Ferro TJ, Blumenstock FA et al. (1990 Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 85 : 1991 1998.
71. MacKinnon JR, O'Brien C, Swa K et al. (1997 Pulsatile ocular blood flow in untreated diabetic retinopathy. Acta Ophthalmol Scand 75 : 661 664.
72. Marmor MF (1990 Hypothesis concerning carbonic anhydrase treatment of cystoid macular oedema: example with epiretinal membrane. Arch Ophthalmol 108 : 1524 1525.
73. Marumo T, Noll T, Schini-Kerth VB et al. (1999 Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor. J Vasc Res 36 : 510 515.
74. Massin P, Girach A, Erginay A et al. (2006 Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 84 : 466 474.
75. Melder RJ, Koenig GC, Witwer BP et al. (1996 During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumour endothelium. Nat Med 2 : 992 997.
76. Meleth AD, Agrón E, Chan CC et al. (2005 Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46 : 4295 4301.
77. Mellor H Parker PJ (1998 The extended protein kinase C superfamily. Biochem J 332 : 281 292.
78. Miller JW (1997 Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 151 : 13 23.
79. Mitamura Y, Tashimo A, Nakamura Y et al. (2002 Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 25 : 2352.
80. Miyamoto K, Hiroshiba N, Tsujikawa A Ogura Y (1998 In vivo demonstration of increased leucocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 39 : 2190 2194.
81. Miyamoto K, Khosrof S, Bursell SE et al. (1999 Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96 : 10836 10841.
82. Miyamoto N, de Kozak J, Jeanny JC, Glotin A, Mascarelli F, Massin P, BenEzra D, Behar-Cohen F (2007 Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50 : 461 470.
83. Morigi M, Angioletti S, Imberti B et al. (1998 Leucocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycaemia in an NF-kB-dependent fashion. J Clin Invest 101 (9 1905 1915.
84. Moss SE, Klein R Klein BE (1998 The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105 : 998 1003.
85. Nagpala PG, Malik AB, Vuong PT et al. (1996 Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 166 : 249 255.
86. Navaratna D, McGuire PG, Menicucci G et al. (2007 Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56 : 2380 2387.
87. Nishikawa T, Edelstein D Brownlee M (2000 The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77 : 26 30.
88. Norgarard K, Feldt-Rasmussen B Deckert T (1991 Is hypertension a major independent risk factor for retinopathy in type I diabetes? Diabet Med 8 : 334 337.
89. Notari L, Miller A, Martínez A et al. (2005 Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 46 : 2736 2747.
90. Okada Y, Yamanaka I, Sakamoto T et al. (2001 Increased expression of angiotensin-converting enzyme in retinas of diabetic rats. Jpn J Ophthalmol 45 : 585 591.
91. Otrock ZK, Makarem JA Shamseddine AI (2007 Vascular endothelial growth factor family and ligands and receptors: review. Blood Cells Mol Dis 38 : 258 268.
92. Patel V, Rassam S, Newson R et al. (1992 Retinal blood flow in diabetic retinopathy. BMJ 305 : 678 683.
93. Patel JI, Tombran-Tink J, Hykin PG et al. (2006 Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular oedema: implications for structural differences in macular profiles. Exp Eye Res 82 : 798 806.
94. Penfold PL, Wen L, Madigan MC et al. (2002 Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 43 (9 3125 3130.
95. Pfeiffer A, Middelberg-Bisping K, Drewes C et al. (1996 Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 19 : 1113 1117.
96. Pfeiffer A, Spranger J, Meyer-Schwickerath R et al. (1997 Growth factor alterations in advanced diabetic retinopathy: a possible role of blood-retina barrier breakdown. Diabetes 46 : 12 (Suppl.) : 26 30.
97. PKC-DMES Study Group (2007 Effect of ruboxistaurin in patients with diabetic macular oedema: 30-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125 : 318 324.
98. Rahman S, Rahman T, Ismail AA et al. (2007 Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9 : 767 780.
99. Robison WG, Laver NM, Jacot JL et al. (1995 Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model. Invest Ophthalmol Vis Sci 36 : 2368 2380.
100. Roy MS Affouf M (2006 Six-year progression of retinopathy and associated risk factors in African-American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol 124 : 1297 1306.
101. Schröder S, Palinski W Schmid-Schönbein GW (1991 Activated monocytes and granulocytes, capillary non-perfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139 : 81 100.
102. Shams N Ianchulev T (2006 Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 19 : 335 344.
103. Sjølie AK, Porta M, Parving HH et al. DIRECT Programme Study Group (2005 The Diabetic Retinopathy Candesartan Trials (DIRECT) programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 6 : 25 32.
104. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R Chaturvedi N DIRECT Programme Study Group (2008 Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo controlled trial. Lancet 372 : 1385 1393.
105. Soliman W, Sander B Jørgensen TM (2007 Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. Acta Ophthalmol Scand 85 : 613 617.
106. Stefánsson E (2001 The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 79 : 435 440.
107. Stefánsson E (2006 Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51 : 364 380.
108. Takahashi H Shibuya M (2005 The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109 : 227 241.
109. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998a Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131 837 853.
110. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998b Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 : 703 713.
111. Usui T, Ishida S, Yamashiro K et al. (2004 VEGF164(165) as the pathological isoform: differential leucocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45 : 368 374.
112. Vinores SA, Xiao WH, Shen J et al. (2007 TNF-α is critical for ischaemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol 182 : 73 79.
113. Vinten M, Larsen M, Lund-Andersen H et al. (2007 Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol Scand 85 : 21 26.
114. Vitale S, Maguire MG, Murphy RP et al. (1995 Clinically significant macular oedema in type I diabetes. Incidence and risk factors. Ophthalmology 102 : 1170 1176.
115. Vuong PT, Malik AB, Nagpala PG et al. (1998 Protein kinase C beta modulates thrombin-induced Ca2+ signalling and endothelial permeability increase. J Cell Physiol 175 : 379 387.
116. Werth DK, Niedel JE Pastan I (1983 Vinculin, a cytoskeletal substrate of protein kinase C. J Biol Chem 258 : 11423 11426.
117. rd Klein RE et al. Global Diabetic Retinopathy Project Group (2003 Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Opthalmology 110 : 1677 1682.
118. Wilkinson-Berka JL (2006 Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 38 : 752 765.
119. Williams B, Gallagher B, Patel H et al. (1997 Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cell in vitro. Diabetes 46 : 1497 1503.
120. Williams R, Airey M, Baxter H et al. (2004 Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18 : 963 983.
121. Wistrand PJ, Schenholm M Lönnerholm G (1986 Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthalmol Vis Sci 27 : 419 428.
122. Yang R, Liu H, Williams I et al. (2007 Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann N Y Acad Sci 1103 : 196 201.